DK1408976T3 - Behandling af ADHD (Attention deficit hyperactivity disorder) - Google Patents

Behandling af ADHD (Attention deficit hyperactivity disorder)

Info

Publication number
DK1408976T3
DK1408976T3 DK02756536T DK02756536T DK1408976T3 DK 1408976 T3 DK1408976 T3 DK 1408976T3 DK 02756536 T DK02756536 T DK 02756536T DK 02756536 T DK02756536 T DK 02756536T DK 1408976 T3 DK1408976 T3 DK 1408976T3
Authority
DK
Denmark
Prior art keywords
adhd
attention deficit
hyperactivity disorder
treatment
deficit hyperactivity
Prior art date
Application number
DK02756536T
Other languages
English (en)
Other versions
DK1408976T5 (da
Inventor
Daniel W Goodman
Daniela Brunner
Original Assignee
Psychogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Psychogenics Inc filed Critical Psychogenics Inc
Publication of DK1408976T3 publication Critical patent/DK1408976T3/da
Application granted granted Critical
Publication of DK1408976T5 publication Critical patent/DK1408976T5/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK02756536.5T 2001-07-20 2002-07-19 Behandling af ADHD (Attention deficit hyperactivity disorder) DK1408976T5 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30682501P 2001-07-20 2001-07-20
US38293102P 2002-05-23 2002-05-23
PCT/US2002/023081 WO2003007956A1 (en) 2001-07-20 2002-07-19 Treatment for attention-deficit hyperactivity disorder

Publications (2)

Publication Number Publication Date
DK1408976T3 true DK1408976T3 (da) 2009-06-29
DK1408976T5 DK1408976T5 (da) 2011-01-10

Family

ID=26975388

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02756536.5T DK1408976T5 (da) 2001-07-20 2002-07-19 Behandling af ADHD (Attention deficit hyperactivity disorder)

Country Status (10)

Country Link
US (5) US7504395B2 (da)
EP (2) EP1408976B3 (da)
JP (1) JP5080716B2 (da)
AT (1) ATE424825T1 (da)
AU (2) AU2002322539B2 (da)
CA (1) CA2453837C (da)
DE (1) DE60231507D1 (da)
DK (1) DK1408976T5 (da)
ES (1) ES2323451T7 (da)
WO (1) WO2003007956A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048906B2 (en) * 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7504395B2 (en) * 2001-07-20 2009-03-17 Psychogenics, Inc. Treatment for attention-deficit hyperactivity disorder
US8134029B2 (en) 2002-09-16 2012-03-13 Sunovion Pharmaceuticals Inc. Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine
US8751031B2 (en) * 2004-02-06 2014-06-10 Zircore, Llc System and method for mass custom manufacturing of dental crowns and crown components
WO2007006003A2 (en) 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
US9066903B2 (en) 2006-02-28 2015-06-30 The United States Of America As Represented By The Department Of Veterans Affairs Pharmacological treatment of Parkinson's disease
TWI553006B (zh) * 2008-05-30 2016-10-11 賽柯傑尼可有限公司 依託拉嗪(eltoprazine)於治療與神經或心理疾病有關之認知失能之症狀的用途
EP2429514A1 (en) * 2009-05-13 2012-03-21 Sunovion Pharmaceuticals Inc. Compositions comprising transnorsertraline and serotonin receptor 1a agonists/ antagonists and uses thereof
NZ597319A (en) * 2009-06-25 2014-06-27 Alcobra Ltd A method for the treatment, alleviation of symptoms of, relieving, improving and preventing a cognitive disease, disorder or condition
WO2011000564A1 (en) 2009-06-30 2011-01-06 Merz Pharma Gmbh & Co. Kgaa Eltoprazine for the treatment of drug addiction
WO2011000562A1 (en) 2009-06-30 2011-01-06 Merz Pharma Gmbh & Co. Kgaa Eltoprazine for the treatment of certain movement disorders
WO2011000563A1 (en) 2009-06-30 2011-01-06 Merz Pharma Gmbh & Co. Kgaa Eltoprazine for the treatment of weight disorders
WO2011000565A1 (en) 2009-06-30 2011-01-06 Merz Pharma Gmbh & Co. Kgaa Eltoprazine for the treatment of anxiety
US8469711B2 (en) * 2009-09-29 2013-06-25 Advanced Training System Llc System, method and apparatus for driver training of shifting
WO2014180556A1 (en) * 2013-05-06 2014-11-13 Merz Pharma Gmbh & Co. Kgaa Arylpiperazines
JP7406285B1 (ja) * 2023-03-09 2023-12-27 国立大学法人島根大学 ビリルビン誘発性神経機能障害、黄疸を伴う精神疾患、又はビリルビンudp-グルクロン酸転移酵素遺伝子変異に起因する精神疾患を治療、予防又は管理するための医薬組成物

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4039653A (en) * 1974-01-23 1977-08-02 Defoney, Brenman, Mayes & Baron Long-acting articles for oral delivery and process
CH653021A5 (fr) 1981-04-24 1985-12-13 Delalande Sa Derives piperidino, piperazino et homopiperazino, n-substitues par un groupe heterocyclique aromatique, leur procede de preparation et composition therapeutique les contenant.
FR2524312B1 (fr) * 1982-04-01 1985-10-04 Tech Cuir Centre Nouvelles formes de micro-encapsulation de substances medicamenteuses par des couches homogenes de collagene natif
ZA848005B (en) 1983-10-17 1985-05-29 Duphar Int Res Blood-pressure lowering piperazine derivatives
ATE81975T1 (de) 1984-12-21 1992-11-15 Duphar Int Res Arzneimittel mit psychotroper wirkung.
EP0185429A1 (en) 1984-12-21 1986-06-25 Duphar International Research B.V New bicyclic heteroaryl piperazines
GB8521494D0 (en) * 1985-08-29 1985-10-02 Zyma Sa Controlled release tablet
US4797286A (en) * 1985-11-12 1989-01-10 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulations
DK93087A (da) 1986-02-27 1987-08-28 Duphar Int Res Hidtil ukendte aryl substituerede (n-piperidinyl)methyl- og (n-piperazinyl)methylazoler med antipsykotiske egenskaber
GB8613689D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
MX173362B (es) 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4889852A (en) 1987-09-11 1989-12-26 Duphar International Research B.V. Anxiolytically active piperazine derivatives
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
CA2004670A1 (en) 1988-12-08 1990-06-08 Jan Hartog Anxiolytically active piperazine derivatives
GB8830312D0 (en) 1988-12-28 1989-02-22 Lundbeck & Co As H Heterocyclic compounds
SE8904361D0 (sv) 1989-12-22 1989-12-22 Astra Ab New chroman and thiochroman derivatives
FR2670491B1 (fr) 1990-12-14 1993-02-05 Adir Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les renfermant.
MX9201991A (es) 1991-05-02 1992-11-01 Jonh Wyeth & Brother Limited Derivados de piperazina y procedimiento para su preparacion.
IT1251144B (it) 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone
GB9125900D0 (en) 1991-12-05 1992-02-05 Wyeth John & Brother Ltd Piperazine derivatives
EP0556889A1 (en) 1992-02-18 1993-08-25 Duphar International Research B.V Method of preparing aryl(homo)piperazines
FR2692264B1 (fr) 1992-06-12 1994-08-05 Adir Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les contenant.
DK148392D0 (da) 1992-12-09 1992-12-09 Lundbeck & Co As H Heterocykliske forbindelser
ATE182367T1 (de) 1992-12-21 1999-08-15 Duphar Int Res Enzymatisches verfahren zur stereoselektiven herstellung einem enantiomer aus einem hetero bicyclischen alkohols
RU2118322C1 (ru) 1993-07-05 1998-08-27 Дюфар Интернэшнл Рисерч Б.В. 2,3-дигидро-1,4-бензодиокси-5-ил-пиперазиновые производные или их соли
WO1995003801A1 (en) * 1993-07-28 1995-02-09 Nippon Shinyaku Co., Ltd. Antidepressant
JPH09503773A (ja) 1993-10-19 1997-04-15 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 5ht−1dレセプター拮抗剤用のベンズアニリド誘導体
EP0650964A1 (en) 1993-11-02 1995-05-03 Duphar International Research B.V 1 2H-1-benzopyran-2-one-8-yl -piperazine derivatives
IL112764A0 (en) 1994-03-18 1995-05-26 Ferrer Int New chromene derivatives
MX9700080A (es) 1994-06-29 1997-04-30 Pfizer Derivados de aril y heteroaril alcoxinaftaleno.
FR2725623A1 (fr) * 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
EP0710481A1 (en) 1994-11-02 1996-05-08 Duphar International Research B.V Use of flesinoxan for cognition enhancement
ATE207063T1 (de) 1994-12-07 2001-11-15 Byk Gulden Lomberg Chem Fab Uracilderivate
US5741789A (en) * 1995-01-17 1998-04-21 Eli Lilly And Company Compounds having effects on serotonin-related systems
WO1997003067A1 (en) 1995-07-13 1997-01-30 Knoll Aktiengesellschaft Piperazine derivatives as therapeutic agents
GB9514901D0 (en) 1995-07-20 1995-09-20 American Home Prod Piperazine derivatives
WO1997007120A1 (en) 1995-08-11 1997-02-27 Smithkline Beecham Plc Biphenyl(thio)amide and biphenylethan(thi)one derivatives, their preparation and their use as 5-ht1d receptor antagonists
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
PT889889E (pt) 1996-03-29 2007-01-31 Duphar Int Res Composto de piperazina e piperidina
US5846982A (en) * 1996-06-14 1998-12-08 Eli Lilly And Company Inhibition of serotonin reuptake
JP2001502327A (ja) 1996-10-15 2001-02-20 アメリカン・ホーム・プロダクツ・コーポレイション 2,3,8,9―テトラヒドロ―7H―1,4―ジオキシノ[2,3―e]インドール―8―オンのアザヘテロサイクリルメチル誘導体
JPH10269708A (ja) 1997-03-25 1998-10-09 Hiroshi Fukuda 多信号用メモリーシステム
FR2760014B1 (fr) 1997-02-27 1999-04-09 Adir Nouveaux composes de 2-amino indane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB9706089D0 (en) 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
DE19730989A1 (de) * 1997-07-18 1999-01-21 Merck Patent Gmbh Piperazin-Derivate
JP2003524571A (ja) 1997-07-25 2003-08-19 ハー・ルンドベック・アクチエゼルスカベット インドール−及び2,3−ジヒドロインドール誘導体、その製造方法及びその使用方法
US5942244A (en) * 1997-07-31 1999-08-24 Farmo-Nat Ltd. Local oral herbal slow release tablets
DE69819266T2 (de) 1997-09-02 2004-07-29 Duphar International Research B.V. Piperidin- und Piperazin Derivate als 5-HT1-Rezeptor-Agonisten
SE9703375D0 (sv) * 1997-09-18 1997-09-18 Astra Ab A new combination
SE9703376D0 (sv) * 1997-09-18 1997-09-18 Astra Ab A new combination
SE9703378D0 (sv) * 1997-09-18 1997-09-18 Astra Ab New compounds
SE9703374D0 (sv) * 1997-09-18 1997-09-18 Astra Ab A new combination
TW530054B (en) 1997-09-24 2003-05-01 Duphar Int Res New piperazine and piperidine compounds
FR2769312B1 (fr) 1997-10-03 1999-12-03 Adir Nouveaux composes de l'indanol, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
IL127497A (en) 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US6310066B1 (en) 1998-04-29 2001-10-30 American Home Products Corp. Antipsychotic indolyl derivatives
US6387904B2 (en) 1998-05-18 2002-05-14 Pfizer Inc Method of treating glaucoma and ischemic retinopathy
DE69910706T2 (de) 1998-05-26 2004-07-08 Pfizer Products Inc., Groton Medikament zur Behandlung von Glaukoma und ischämischer Retinopathie
GB9812523D0 (en) * 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
WO1999065887A1 (en) 1998-06-15 1999-12-23 American Home Products Corporation Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents
US6376494B1 (en) 1998-06-15 2002-04-23 American Home Products Corporation Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents
UA71590C2 (en) 1998-11-13 2004-12-15 Duphar Int Res Piperazine and piperidine derivatives
US6242448B1 (en) 1998-12-17 2001-06-05 American Home Products Corporation Trisubstituted-oxazole derivatives as serotonin ligands
WO2000040554A1 (en) 1999-01-07 2000-07-13 American Home Products Corporation Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression
US6313126B1 (en) 1999-01-07 2001-11-06 American Home Products Corp Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression
AR022303A1 (es) 1999-01-22 2002-09-04 Lundbeck & Co As H Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
US6306859B1 (en) 1999-03-02 2001-10-23 American Home Products Corporation N-substituted imide derivatives with serotonergic activity
ES2162731B1 (es) 1999-06-04 2003-02-16 Faes Fabrica Espanola De Produ Nuevas arilpiperacilnilalquil-3(2h)-piridacinonas.
DK1204658T3 (da) 1999-07-29 2003-09-01 Lilly Co Eli Benzofurylpiperazin-serotoninagonister
CA2378878A1 (en) 1999-07-29 2001-02-08 Jeffrey Thomas Mullaney Benzofurylpiperazines and benzofurylhomopiperazines: serotonin agonists
NZ517900A (en) 1999-08-23 2003-08-29 Solvay Pharm Bv Phenylpiperazines useful as serotonin reuptake inhibitors
AR027133A1 (es) 1999-12-30 2003-03-12 Lundbeck & Co As H Derivados de heteroarilo, su preparacion y uso.
US20030186838A1 (en) 2000-05-12 2003-10-02 Feenstra Roelof W. Use of compounds having combined dopamine d2, 5-ht1a and alpha adrenoreceptor agonistic action for treating cns disorders
AU6392701A (en) 2000-05-12 2001-11-20 Solvay Pharm Bv Piperazine and piperidine compounds
US20020016334A1 (en) 2000-07-31 2002-02-07 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD)
DE10041574A1 (de) 2000-08-24 2002-03-07 Merck Patent Gmbh Chromenonderivate
DE10043659A1 (de) 2000-09-05 2002-03-14 Merck Patent Gmbh Arylpiperazinderivate
US7034029B2 (en) * 2000-11-02 2006-04-25 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
EP1343756A2 (en) * 2000-11-02 2003-09-17 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
US6469007B2 (en) 2000-11-28 2002-10-22 Wyeth Serotonergic agents
ES2188344B1 (es) 2000-11-29 2004-09-16 Laboratorios Vita, S.A. Compuestos derivados de benzotiofeno, su procedimiento de obtencion y utilizacion de los mismos.
AR032711A1 (es) 2001-02-21 2003-11-19 Solvay Pharm Bv Derivados de fenilpiperazina, un metodo para la preparacion de los mismos y una composicion farmaceutica que los contiene
UA75407C2 (en) 2001-06-29 2006-04-17 Lundbeck & Co As H Heteroaryl derivatives of pyridine and pyrimidine, pharmaceutical composition and use thereof
US7504395B2 (en) * 2001-07-20 2009-03-17 Psychogenics, Inc. Treatment for attention-deficit hyperactivity disorder
HU227237B1 (en) 2001-09-27 2010-12-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Substituted alkylpyridazinone derivatives, process for their preparation, pharmaceutical compositions containing them
ITMI20012060A1 (it) 2001-10-05 2003-04-05 Recordati Chem Pharm Nuovi eterocilcli n-acilati
EP1336406A1 (en) 2002-02-14 2003-08-20 Solvay Pharmaceuticals B.V. Partial dopamine-D2 receptor agonist plus serotonin and/or noradrenaline inhibitory activity
WO2003074518A1 (en) 2002-03-06 2003-09-12 Merck Patent Gmbh Thiazole derivatives and their use d2- and 5-ht1a-receptor ligands
KR20040091720A (ko) 2002-03-12 2004-10-28 와이어쓰 N1-(2'-피리딜)-1,2-프로판디아민 설팜산의 제조방법 및생물학적 활성 피페라진 합성시의 이의 용도
CN101492383A (zh) 2002-03-12 2009-07-29 惠氏公司 制备手性1,4-二取代哌嗪的方法
MXPA04008729A (es) 2002-03-12 2005-07-13 Wyeth Corp Proceso para sintetizacion de piperazinas n-arilicas quirales.
UA76877C2 (uk) 2002-05-13 2006-09-15 Ф.Хоффманн-Ля Рош Аг Похідні бензоксазину як 5-нт6 модулятори і їх застосування
US20040072839A1 (en) 2002-06-14 2004-04-15 Amedeo Leonardi 1-Phenylalkylpiperazines
US20040002500A1 (en) 2002-06-28 2004-01-01 Fabre Kramer Pharmaceutical, Inc. Methods for treating attention deficit disorder
US7067518B2 (en) 2002-09-05 2006-06-27 Wyeth Pyridinyl-methyl-ethyl cyclohexanecarboxamides as serotonergic agents
US7153849B2 (en) 2002-09-12 2006-12-26 Wyeth Antidepressant arylpiperazine derivatives of hetrocycle-fused benzodioxans
PT1562918E (pt) 2002-11-08 2008-03-12 Hoffmann La Roche Benzoxazinonas substituídas e as suas utilizações
HU227592B1 (en) 2002-11-13 2011-09-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Use of substituted alkyl-piridazinone derivatives for the treatment of memory decline and learning malfunctions
US20040147581A1 (en) 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
GB0227240D0 (en) 2002-11-21 2002-12-31 Glaxo Group Ltd Compounds
DE10259244A1 (de) 2002-12-17 2004-07-01 Merck Patent Gmbh N-(Indolethyl-)cycloamin-Verbindungen
US20050004105A1 (en) 2003-01-29 2005-01-06 Emer Leahy Treatment for a attention-deficit hyperactivity disorder
JP2006515341A (ja) 2003-03-03 2006-05-25 エフ.ホフマン−ラ ロシュ アーゲー 5−ht6調節物質として使用するための2,5−および2,6−置換テトラヒドロイソキノリン
JP2007502856A (ja) 2003-05-16 2007-02-15 ファイザー・プロダクツ・インク 精神病性障害および抑うつ性障害の治療
EP1626722A1 (en) 2003-05-16 2006-02-22 Pfizer Products Inc. Method for enhancing cognition using ziprasidone
KR20060009938A (ko) 2003-05-16 2006-02-01 화이자 프로덕츠 인코포레이티드 양극성 장애 및 연관된 증상의 치료
BRPI0410419A (pt) 2003-05-16 2006-05-30 Pfizer Prod Inc tratamento para a ansiedade com ziprasidona
US20050065158A1 (en) 2003-07-16 2005-03-24 Pfizer Inc. Treatment of sexual dysfunction
GB0316915D0 (en) 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
US7435738B2 (en) 2003-08-18 2008-10-14 Solvay Pharmaceuticals, Inc. Stable crystalline form of bifeprunox mesylate (7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate)
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
AU2004299201B2 (en) 2003-12-09 2009-12-03 F. Hoffmann-La Roche Ag Benzoxazine derivatives and uses thereof
EP1699488A2 (en) 2003-12-23 2006-09-13 Pfizer Products Incorporated Therapeutic combination for cognition enhancement and psychotic disorders

Also Published As

Publication number Publication date
US20030050308A1 (en) 2003-03-13
DE60231507D1 (de) 2010-07-01
US7557109B2 (en) 2009-07-07
EP2036547A2 (en) 2009-03-18
EP1408976A1 (en) 2004-04-21
JP2004538282A (ja) 2004-12-24
EP1408976A4 (en) 2007-05-16
EP1408976B1 (en) 2009-03-11
WO2003007956A1 (en) 2003-01-30
AU2007254677B2 (en) 2009-11-12
US7504395B2 (en) 2009-03-17
CA2453837A1 (en) 2003-01-30
AU2002322539B2 (en) 2007-09-27
EP2036547A3 (en) 2009-12-23
EP1408976B3 (en) 2010-08-25
US20090104261A1 (en) 2009-04-23
CA2453837C (en) 2011-10-04
US20110008425A1 (en) 2011-01-13
DK1408976T5 (da) 2011-01-10
HK1065478A1 (en) 2005-02-25
US20120070494A1 (en) 2012-03-22
JP5080716B2 (ja) 2012-11-21
ES2323451T3 (es) 2009-07-16
ES2323451T7 (es) 2011-08-01
ATE424825T1 (de) 2009-03-15
US20060004023A1 (en) 2006-01-05
AU2007254677A1 (en) 2008-01-24

Similar Documents

Publication Publication Date Title
DK1408976T5 (da) Behandling af ADHD (Attention deficit hyperactivity disorder)
ATE296634T1 (de) (s,s)-reboxetin zur behandlung von fibromyalgie und anderen somatoformen störungen
DK1503788T3 (da) Behandling af alpha-galactosidase A-deficiens
DE60237725D1 (de) Vervendung von dexrazoxane in der prävention und behandlung der alzeheimer-krankheit
ATE542801T1 (de) Zur behandlung von neoplastischen krankheiten, entzündlichen erkrankungen und erkrankungen des immunsystems geeignete 2,4-pyrimidindiamine
PT1339399E (pt) Combinacoes de drogas (e.g., clorpromazina e pentamidina) para o tratamento de desordens neoplasicas
DE602004017037D1 (de) 2,3-dihydro-6-nitroimidazoä2,1-büoxazolverbindungen zur behandlung von tuberkulose
CY1107911T1 (el) Διαταξη αφαιρεσεως
ATE316787T1 (de) Kombination von fenofibrat und von coenzym q10 für die behandlung der endotheliaal missfunktion
DK1855677T3 (da) 3,11 B-CIS-dihydrotetrabanezin til behandling af skizofreni og andre psykoser
CY1109238T1 (el) Δισκιο περιεχον σετιριζινη και ψευδοεφεδρινη
DK1343822T3 (da) Middel til diagnosticering og behandling af CTCL
DK1491212T3 (da) Middel til behandling af søvnforstyrrelser
BRPI0418589A (pt) composições farmacêuticas e métodos para tratamento por insulina
ATE319439T1 (de) Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd
ATE400564T1 (de) Ppar alpha selektive verbindungen zur behandlung von dyslipidämie und anderen lipidstörungen
DE60206289D1 (de) Verwendung von bibn4096 in kombination mit anderen migränemitteln zur behandlung von migräne
BR0313588A (pt) Métodos para o tratamento da demência com base em apo e genótipo
DE60335610D1 (de) Neoplasma-spezifische antikörper und deren verwendungen
DE60128009D1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
DK1603584T3 (da) Aplidine til behandling af multipelt myelom
DK1523985T3 (da) Ikke-radioaktivt strontiumholdigt middel til behandling af kræft
DE50300918D1 (de) Anlage zum sterilisieren, pasteurisieren und/oder desinfizieren pump- oder rieselfaehiger medien
ATE443262T1 (de) Molekulardiagnoseverfahren und behandlung von demenz mit lewy-körperchen
SE0003126D0 (sv) Method of treatment